


DIRUCOTIDE

straightforward

BIOMS
MEDICAL™

TSX:MS



A black and white photograph of a garden path. The path is a narrow, dark strip running vertically through the center of the image. On either side of the path, there are various plants and flowers. To the left, there are dark, leafy plants with small white flowers. To the right, there are lighter-colored, more delicate plants with small white flowers. The overall scene is a lush, natural garden setting.

**Driven by our belief
that every human being
deserves a life filled with
promise and opportunity,
a life unimpeded by pain
and fear, a life fully lived.**

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of multiple sclerosis (MS).

BioMS Medical is a publicly traded company on the Toronto Stock Exchange (Symbol: MS)

constant



**We are resolved to deliver an effective
and safe treatment for people with MS.**

**Only novel agent for secondary progressive MS
in Phase III trials worldwide**

Solid international patent portfolio

Partnered with Eli Lilly and Company

World-class scientific advisory board

Highly effective management team

what is multiple sclerosis?

Multiple sclerosis (MS) is considered to be an auto-immune disease caused when a patient's own immune system erroneously attacks the myelin coating which insulates the nerves in the brain and spinal column. When the myelin is destroyed or damaged, the electrical impulses to and from the brain are disrupted, causing a progressive decline of motor and cognitive functions characterized by episodes of paralysis, blindness, sensory disturbances and cognitive impairment.

***MS is usually diagnosed between the ages of 15 to 40, during the career and family building years. The disease occurs in more women than men, and is seen most commonly in people of northern European background.**



Relapsing-remitting (RRMS)

Characterized by short periods when new symptoms appear or old ones intensify, followed by intervals when symptoms improve or stabilize. 80-85% of MS patients are initially diagnosed with RRMS.

Secondary-progressive (SPMS)

SPMS is characterized by steady disease progression with or without flare-ups or remissions. SPMS patients account for 40-45% of total MS patient population.

Primary-progressive (PPMS)

Generally exhibits a slow but nearly continuous worsening of the disease from onset. 10-15% of MS patients have PPMS when first diagnosed.

Progressive-relapsing (PRMS)

Steadily worsening disease course from the onset, plus acute attacks with or without recovery. Rare: 5% or less of MS patients.

Dirucotide (MBP8298) is based on the research by Dr. Ken Warren and Ms. Ingrid Catz at the Multiple Sclerosis Patient Care and Research Clinic, Department of Medicine, University of Alberta, Edmonton, Canada.



Ms. Ingrid Catz and Dr. Ken Warren:
co-inventors of dirucotide.

Underserved market

MS is thought to affect 2.5 million people worldwide including approximately 75,000 in Canada, 400,000 in the United States and over 500,000 in Europe.

Of the few existing treatments for secondary progressive MS, most are only moderately effective and can produce undesirable side effects.

The current market for RRMS is over \$7 Billion. The market potential for SPMS is estimated to be over \$5 Billion.

dirucotide

Potential blockbuster market opportunity

Dirucotide (MBP8298) is a synthetic peptide that is an exact molecular copy of the portion of myelin basic protein (MBP) most susceptible to immune attack in MS patients with HLA haplotypes DR-2 or DR-4 (up to 75% of all MS patients). Dirucotide (MBP8298) delivered intravenously at six month intervals has shown to induce and maintain tolerance against ongoing immune attack at this molecular site.

Phase II and long-term follow-up treatment of MS patients with dirucotide (MBP8298), published in the *European Journal of Neurology* showed that dirucotide (MBP8298) safely delayed the median time to disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.

Dirucotide (MBP8298) has successfully completed Phase I and II clinical trials and has more than 1,000 combined patient years of treatment experience.

There has never been a more optimistic time for patients with secondary progressive MS.

uncompromising



PIVOTAL PHASE III GLOBAL TRIALS



A pivotal Phase III trial in Canada and Western Europe evaluating dirucotide (MBP8298) for the treatment of SPMS. This randomized, double-blind trial is fully recruited with 611 patients in 10 countries at 47 trial sites, who are being administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years.



An open-label, follow-on trial to MAESTRO-01.



A pivotal Phase III U.S. trial evaluating dirucotide (MBP8298) for the treatment of SPMS. The trial is a randomized, double-blind study fully recruited with approximately 510 patients at 68 trial sites.



A Phase II trial in Europe evaluating dirucotide (MBP8298) for the treatment of relapsing remitting multiple sclerosis (RRMS). The trial is a randomized, double-blind study fully recruited with 218 patients in 6 countries at 24 sites.

enterprising



UNPRECEDENTED LICENSING DEAL

December 17, 2007, BioMS Medical announced a licensing and development agreement with Eli Lilly and Company:

- > Lilly is granted exclusive worldwide rights to dirucotide (MBP8298)**
- > BioMS and Lilly will collaborate on the development of dirucotide (MBP8298)**
- > Lilly will be responsible for future research and development, manufacturing and marketing activities**
- > BioMS received:**
 - an up front payment of US \$87 million**
 - milestone payment of US \$10 million based on positive interim analysis of MAESTRO-01**
 - sales and development milestones of up to US \$400 million**
 - escalating royalties on sales if dirucotide (MBP8298) is successfully commercialized**

“Having witnessed the devastating effects of multiple sclerosis first hand, it is clear to me how large an impact dirucotide (MBP8298) will have...and how critical it is that we succeed.”

Clifford Giese



Clifford Giese
Chairman



Kevin Giese
President and CEO

Straightforward

Global licensing and development agreement with Lilly

Strong cash position to responsibly execute our business plan

Currently the only novel agent in Phase III clinical trials for SPMS worldwide

Dirucotide (MBP8298) showed a 5-year delay in median time to progression of MS in Phase II trials

Over 1,000 combined patient years of treatment experience

Positive interim analysis for MAESTRO-01

FDA fast track designation for MAESTRO-03

Exclusive rights to international patent portfolio of potential blockbuster drug with underserved market worldwide

Formulating plans for successful commercialization of dirucotide (MBP8298) pending positive trial results and regulatory approvals

Listed on Toronto Stock Exchange (Stock Symbol “MS”)

Dirucotide (MBP8298) Patent Portfolio

- **Over 100 patents issued in over 30 countries**
- **Claims for composition, use, delivery**
- **Expiration dates up to 2017**

Endpoint

a better life for people with MS.

BIOMS
M E D I C A L TM

BioMS Medical Corp
6030 - 88 Street
Edmonton, Alberta
T6E 6G4

Ph: 780.413.7152
Fx: 780.408.3040
www.biomsmedical.com

This information may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS Medical with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.